JUSTIN SMITH: Open Payments
NPI 1982015590 · ROME, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$691 in 42 payments from 11 companies in 2025. Trend: 2023 $479 · 2024 $569 · 2025 $691
Food & beverage: $675Education: $16
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $269 |
| AstraZeneca Pharmaceuticals LP | 5 | $97 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $87 |
| PFIZER INC. | 4 | $78 |
| Amgen Inc. | 2 | $48 |
| Abbott Laboratories | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Exact Sciences Corporation | 1 | $18 |
Products named: VRAYLAR, CAPLYTA, UBRELVY, ELIQUIS, EVENITY, FARXIGA, AIRSUPRA, QULIPTA.
Industry payments across GA — which companies pay providers there.
